Joinn Laboratories (06127): One warning of profit decline has become a market indicator. Will "rate cut" be the final key for valuation rebound?
On July 10, Joinn Laboratories (06127) closed at a record low of HK$6.62. However, the company received a boost after the release of a profit warning that evening. According to the AI Finance and Economics app, on the evening of July 10, Joinn Laboratories issued a profit warning, expecting revenue of approximately 0.719 billion yuan to 0.973 billion yuan (RMB, same below) from January to June 2024. Compared with the same period last year, it will decrease by about 38.6417 million yuan to 0.293 billion yuan, a year-on-year decline of about 3.8% to 28.9%.
JOINN Laboratories (China) Flags Losses in H1; Shares Rise 10%
JOINN Laboratories(China) (HKG:6127, SHA:603127) expects a net loss attributable to the shareholders of 136.3 million yuan to 184.4 million yuan, compared with a profit of 90.6 million yuan in the
Nomura Adjusts Joinn Laboratories' Price Target to 12.27 Yuan From 17.37 Yuan, Keeps at Neutral
Joinn Laboratories (SHA:603127) has an average rating of outperform and price targets ranging from 10 yuan to 21.50 yuan, according to analysts polled by Capital IQ.Price (RMB): ¥13.71, Change: ¥+1.25
Hong Kong stock market active | CXO concept stocks rebounded in early trading, overseas loosening is expected to drive investment and financing to pick up, and there are frequent policies supporting innovative drugs.
CXO Concept Stocks rebounded in early trading, and as of the time of publication, Joinn Laboratories (06127) rose 10.73%, to HKD 7.33; Genscript Bio (01548) rose 5.19%, to HKD 9.53; Pharmaron (03759) rose 5.13%, to HKD 8.6; Tigermed (03347) rose 4.56%, to HKD 28.65.
Hong Kong stocks are fluctuating | Joinn Laboratories (06127) rose more than 6%, with a expected net loss of about 0.136 billion yuan to 0.184 billion yuan in the first half.
Joinn Laboratories (06127) rose over 6%. As of press time, it increased by 6.65%, with a price of HKD 80.50 and a turnover of 5.129 million Hong Kong dollars.
Joinn Laboratories 1H23 Revenue Was CNY1.01B; Net CNY90.63M >603127.SH
Joinn Laboratories 1H23 Revenue Was CNY1.01B; Net CNY90.63M >603127.
Joinn Laboratories: Changes in Market Demand, Increased Competition Weighed on Results >603127.SH
Joinn Laboratories: Changes in Market Demand, Increased Competition Weighed on Results >603127.
Joinn Laboratories Expects to Swing to Loss in 1H >603127.SH
Joinn Laboratories Expects to Swing to Loss in 1H >603127.
Joinn Laboratories Beijing's interim performance forecast for 2024.
JOINN Laboratories Projects H1 2024 Losses
Express News | Joinn Laboratories China - Expected Decrease in Rev Due to Impact of Investment and Financing Enthusiasm in Pharmaceutical Industry, Among Others
Express News | Joinn Laboratories China Sees Net Loss Attributable for Hy RMB184.4 Mln to Loss of RMB136.3 Mln
Express News | Joinn Laboratories China Sees Hy Revenue RMB719.5 Mln to RMB973.4 Mln
JOINN: ESTIMATED RESULTS FOR THE HALF YEAR OF 2024
Joinn Laboratories (China) to Repurchase Over 400,000 Shares for 42.37 Yuan per Share
Joinn Laboratories(China) (HKG:6127, SHA:603127) plans to complete the repurchase of 411,365 restricted A shares granted under the 2021 incentive scheme for 42.37 yuan per A share, according to a
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
JOINN Laboratories Cancels Incentive Scheme Shares
Joinn Laboratories (06127) repurchased and cancelled 0.411365 million restricted A-stock shares.
Zhao Yan New Drug (06127) announced that due to the continuous changes in the macroeconomic and market environment at home and abroad, it will be difficult to achieve the expected incentive goals and effects if the 2021 A-share restricted stock incentive plan continues to be implemented. In order to better protect the interests of the company, shareholders and employees, and effectively stimulate the enthusiasm of core employees, after careful consideration and in combination with the actual situation of the company, in accordance with the relevant provisions of the "Management Measures for Stock Incentives of Listed Companies", the company has decided to terminate the 2021 A-share restricted stock incentive plan and repurchase and cancel the restricted stocks that have been granted but have not yet been released from restriction. In summary, the company
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Getting In Cheap On Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Is Unlikely
There wouldn't be many who think Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) price-to-sales (or "P/S") ratio of 4.3x is worth a mention when the median P/S for the Life Sciences industry in Chin
No Data